Deferiprone-related arthropathy of the knee in a thalassemic patient: report of a case and review of the literature.
Deferiprone (DFP), the first oral iron chelator, has been used in patients with beta-thalassemia major to reduce serum ferritin levels and total iron burden, leading to decreased cardiac iron levels. Major side effects include embryotoxicity, agranulocytosis, zinc deficiency and gastrointestinal disorders, while arthropathy is rarely reported. Herein, we present a 29-year-old male patient with beta-thalassemia major, who developed severe arthritis of both knees while under deferiprone therapy. Arthritis was managed successfully with non-steroid antiinflammatory drugs after DFP withdrawal.
Vlachaki
Efthimia
E
Thalassemic Unit, Hippokration General Hospital, Thessaloniki, Greece. efivlachaki@yahoo.gr
Tselios
Konstantinos
K
Perifanis
Vasilios
V
Tsatra
Ioanna
I
Tsayas
Ioannis
I
D000328:Adult; D001168:Arthritis / Q000139:chemically induced*; D000077543:Deferiprone; D006801:Humans; D007502:Iron Chelating Agents / Q000009:adverse effects*; D007719:Knee Joint; D008297:Male; D011728:Pyridones / Q000009:adverse effects*; D017086:beta-Thalassemia / Q000188:drug therapy*
D007502:Iron Chelating Agents; D011728:Pyridones; D000077543:Deferiprone